Market closed
Tempest Therapeutics/$TPST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tempest Therapeutics
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Ticker
$TPST
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
24
Website
TPST Metrics
BasicAdvanced
$24M
-
-$19.50
-2.28
-
Price and volume
Market cap
$24M
Beta
-2.28
52-week high
$8.23
52-week low
$5.43
Financial strength
Current ratio
2.213
Quick ratio
2.129
Long term debt to equity
42.57
Total debt to equity
80.336
Interest coverage (TTM)
-31.93%
Management effectiveness
Return on assets (TTM)
-56.43%
Return on equity (TTM)
-182.35%
Valuation
Price to book
1.21
Price to tangible book (TTM)
1.21
Price to free cash flow (TTM)
-0.439
Growth
Earnings per share change (TTM)
-21.61%
3-year earnings per share growth (CAGR)
-41.44%
TPST News
AllArticlesVideos
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewsWire·1 week ago
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
GlobeNewsWire·3 weeks ago
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Tempest Therapeutics stock?
Tempest Therapeutics (TPST) has a market cap of $24M as of May 09, 2025.
What is the P/E ratio for Tempest Therapeutics stock?
The price to earnings (P/E) ratio for Tempest Therapeutics (TPST) stock is 0 as of May 09, 2025.
Does Tempest Therapeutics stock pay dividends?
No, Tempest Therapeutics (TPST) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Tempest Therapeutics dividend payment date?
Tempest Therapeutics (TPST) stock does not pay dividends to its shareholders.
What is the beta indicator for Tempest Therapeutics?
Tempest Therapeutics (TPST) has a beta rating of -2.28. This means that it has an inverse relation to market volatility.